A Dose-Escalation Safety And Pharmacokinetics/Pharmacodynamics (PK/PD) Study Of Macimorelin(Macrilen) In Pediatric Patients Atleast Three Years Old
Latest Information Update: 13 Aug 2024
Price :
$35 *
At a glance
- Drugs Macimorelin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 06 Aug 2024 According to a COSCIENS Biopharma media release, the Aeterna Zentaris Inc name has been changed to COSCIENS Biopharma.
- 30 Mar 2017 New trial record
- 07 Mar 2017 According to an Aeterna Zentaris media release, the Pediatric Committee (PDCO) of the European Medicines Agency agreed to Aeterna Zentaris Pediatric Investigation Plan (PIP) and also agreed that the company may defer conducting the studies defined in the PIP until it files an MAA for Macimorelin for the treatment of somatotropin-deficiency in adults.